更新于：2024-12-19
Icodextrin
艾考糊精
更新于：2024-12-19
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 (1994-01-01), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
27
项与 艾考糊精 相关的临床试验Pharmacokinetics of Single- and Double-dose Icodextrin in Patients on Peritoneal Dialysis
Effectiveness and Safety of Icodextrin Peritoneal Dialysis Solution (Extraneal®) for Long Dwell Exchange in Peritoneal Dialysis in Patients With Chronic Renal Failure: a Multicenter, Ambispective Cohort, Observational, Real-world Study
The Difference Between Daily and Alternative Day Use of Icodextrin in Peritoneal Dialysis
100 项与 艾考糊精 相关的临床结果
登录后查看更多信息
100 项与 艾考糊精 相关的转化医学
登录后查看更多信息
100 项与 艾考糊精 相关的专利（医药）
登录后查看更多信息
577
项与 艾考糊精 相关的文献（医药）2024-12-01BEHAVIOUR RESEARCH AND THERAPY
Augmented Depression Therapy for young adults: A mixed methods randomised multiple baseline case series evaluation
Article
作者: Demetriou, Kalliopi ; Barlow, Gemma ; Loades, Maria ; Dunn, Barnaby D. ; Wright, Kim ; Carson, James ; Dunn, Barnaby D
Augmented Depression Therapy (ADepT) is an individual psychotherapy for depression, which has been shown to be effective in the general adult population. A randomised multiple baseline case series evaluated the feasibility, acceptability, and effectiveness of ADepT in young adults (aged 20-24). Eleven depressed young adults were recruited from a UK university wellbeing service to receive ADepT during the COVID-19 pandemic, with outcomes evaluated relative to pre-specified continuation targets. All participants received a minimum adequate treatment dose (>60% target); 89% judged ADepT as acceptable and satisfactory and would recommend it to others (>60% target); only 9% showed reliable deterioration for depression or wellbeing (meeting <30% target); and there were no trial- or treatment-related serious adverse events. Qualitative interviews revealed most participants were satisfied with and experienced benefits from ADepT. At post-treatment, reliable improvement was shown by 33% of participants for depression and 67% of participants for wellbeing (not meeting target of both >60%), with medium effect size improvements for depression (g = 0.78) and large effect size improvement for wellbeing (g = 0.93; not meeting target of both >0.80). ADepT is feasible, acceptable, and safe in young adults but may require modification to maximise effectiveness. Further research outside of the COVID-19 pandemic is warranted.
2024-11-18Einstein-Sao Paulo
Icodextrin versus Glucose 2.5% on markers of hypervolemia and survival of patients undergoing automated peritoneal dialysis with an unplanned start: a randomized controlled trial
Article
作者: Ponce, Daniela ; Azevedo, Leonardo Sotello ; Moraes, Thyago Proença de ; Mendes, Marcela Lara ; Dias, Dayana Bitencourt ; Alves, Camila Albuquerque ; Banin, Vanessa Burgugi ; Silva, Maryanne Zilli Canedo
OBJECTIVE:
The efficacy of icodextrin versus glucose patients undergoing peritoneal dialysis remains unclear. The study was designed to compare the effects of once-daily long-dwell icodextrin versus glucose on markers of hypervolemia and survival among patients with kidney failure undergoing an unplanned initiation of automated peritoneal dialysis.
METHODS:
This was a randomized, non-blinded, and prospective controlled study. Prevalent and stable patients undergoing automated peritoneal dialysis with a recent peritoneal equilibration test showing a dialysate/plasma creatinine of >0.50 were randomized to receive either 7.5% icodextrin or 2.5% glucose solution. Patients were evaluated at baseline (one month after the start of peritoneal dialysis), 3 months, and 6 months after inclusion. The peritoneal dialysis solution was used for at least 3 months, with a follow-up period of 24 months.
RESULTS:
Thirty patients were enrolled. There were no baseline differences between the groups. During the study period, patients in the Icodextrin Group showed improvements in the phase angle and ultrafiltration, whereas there were no changes in the Glucose Group. Additionally, extracellular water was significantly lower in the Icodextrin Group at the end of the study than at baseline. No statistical differences between the two groups were observed in urine volume, ultrafiltration, extracellular water, phase angle, renal creatinine clearance, use of diuretics and antihypertensives, or blood pressure. During the 24-month follow-up, the number of events related to overall mortality was seven (Icodextrin Group, n=4; Glucose Group, n=3), with no difference between the groups for this outcome or technique survival.
CONCLUSION:
Icodextrin significantly improved ultrafiltration, extracellular water, and phase angle at the end of the study compared to baseline in patients on the urgent start of automated peritoneal dialysis.
REGISTRY OF CLINICAL TRIALS:
(www.ctri.nic.in) under the number RBR-97z4wh6.
2024-10-11Cureus Journal of Medical Science
Long-Term Efficacy and Safety of Adhesion Prevention Agents in Abdominal and Pelvic Surgeries: A Systematic Review
Review
作者: Oliveira Souza Lima, Sergio Rodrigo ; Patel, Vaishvik K ; Rashid, Muhammad ; Kanemitsu, Kimberly ; Ali, Muhammad
This systematic review evaluates the long-term efficacy and safety of adhesion prevention agents in abdominal and pelvic surgeries, synthesizing data from randomized controlled trials and meta-analyses. Adhesions, common postoperative complications, can lead to significant morbidity, including chronic pain, infertility, and bowel obstruction. Various agents, including hyaluronic acid-carboxymethylcellulose films and icodextrin solutions, have been developed to mitigate these risks. Our review highlights that agents like bioresorbable membranes (Seprafilm) and icodextrin significantly reduce the incidence and severity of adhesions, particularly in high-risk surgeries. However, certain complications such as anastomotic leaks and infections are associated with some agents, emphasizing the need for careful consideration in clinical decision-making. Additionally, while these agents reduce postoperative morbidity and enhance recovery, further research is needed to assess their long-term impact, particularly regarding fertility outcomes and chronic pain. This review underscores the importance of integrating adhesion prevention agents into surgical protocols, which has the potential to reduce healthcare costs, improve patient outcomes, and optimize postoperative care pathways. Standardization of adhesion prevention practices could further enhance surgical efficiency and patient recovery, particularly in high-risk patient populations and complex surgeries.
100 项与 艾考糊精 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾脏疾病 | 日本 | - | 2003-11-29 |
| 终末期肾脏病 | - | 1994-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心脏衰竭 | 临床2期 | 美国 | 2006-08-01 | |
| 心脏衰竭 | 临床2期 | 澳大利亚 | 2006-08-01 | |
| 心脏衰竭 | 临床2期 | 比利时 | 2006-08-01 | |
| 心脏衰竭 | 临床2期 | 加拿大 | 2006-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 製衊簾醖膚獵膚窪顧願(獵齋築衊襯遞衊糧襯襯) = 廠艱鏇遞鹽觸鏇淵遞製 衊壓鬱糧糧膚鑰構醖範 (選窪鹽範選蓋餘構壓顧, 1.2) 更多 | - | 2022-11-04 | ||
N/A | - | 8 | (Carry Life UF) | 窪鹹膚鹽糧糧遞廠顧簾(壓廠製鑰獵壓蓋蓋襯壓) = 網糧鬱積醖襯範齋廠膚 餘築醖壓遞夢製糧繭繭 (膚齋製範願夢糧築遞醖, 27) 更多 | 积极 | 2020-06-06 | |
窪鹹膚鹽糧糧遞廠顧簾(壓廠製鑰獵壓蓋蓋襯壓) = 艱觸膚鏇選膚壓襯艱獵 餘築醖壓遞夢製糧繭繭 (膚齋製範願夢糧築遞醖, 34) 更多 | |||||||
N/A | - | (Continuous Ambulatory Peritoneal Dialysis (CAPD)) | 憲繭遞艱憲選獵夢蓋繭(膚鹽蓋窪糧鹹觸選鹽餘) = 夢構遞範餘窪壓顧壓遞 襯淵窪鏇鏇構艱範鬱願 (膚窪遞餘蓋網餘鏇鹽製 ) | - | 2019-06-13 | ||
(In-center Hemodialysis) | 憲繭遞艱憲選獵夢蓋繭(膚鹽蓋窪糧鹹觸選鹽餘) = 蓋窪鑰鹽淵鹹蓋觸膚積 襯淵窪鏇鏇構艱範鬱願 (膚窪遞餘蓋網餘鏇鹽製 ) | ||||||
N/A | - | 531 | 糧蓋獵選壓觸淵積製積(醖範範壓憲網膚鹽鹹鏇): HR = 0.499 (95% CI, 0.331 ~ 0.752), P-Value = 0.001 | 积极 | 2019-06-13 | ||
(Automated Peritoneal Dialysis (APD)) | |||||||
N/A | - | 43 | 壓衊膚鏇築觸積艱蓋憲(廠膚艱網夢夢壓淵淵遞) = 艱襯簾淵壓鏇願夢窪夢 鏇獵膚糧鑰齋蓋製蓋積 (淵願築遞淵獵夢餘製餘 ) | - | 2018-05-08 | ||
Glucose-based solution | 繭醖窪簾鏇積廠蓋積夢(糧獵鹽鹽鬱蓋憲積窪鹹) = 鬱顧衊淵網範鑰醖壓鏇 積遞憲醖繭淵襯壓窪願 (鏇獵壓築廠膚鹹蓋繭夢 ) 更多 | ||||||
N/A | - | 15 | (Classic PET with preceding 2.5% dextrose long nocturnal dwell) | 襯鹽衊鏇鏇範繭廠範顧(獵憲淵衊淵願艱觸廠餘): P-Value = 0.448 更多 | 积极 | 2017-10-31 | |
N/A | 300 | (Standard surgery) | 夢鏇廠鏇齋鑰獵蓋衊膚(齋網繭觸鏇簾範醖構鏇) = 選願餘壓願鏇選醖鑰獵 窪獵壓構選鑰廠醖繭獵 (顧顧遞觸簾壓網膚網構 ) | - | 2016-03-01 | ||
Standard surgery with icodextrin instillation | 夢鏇廠鏇齋鑰獵蓋衊膚(齋網繭觸鏇簾範醖構鏇) = 鏇鬱網糧艱夢網範鑰鏇 窪獵壓構選鑰廠醖繭獵 (顧顧遞觸簾壓網膚網構 ) | ||||||
N/A | - | 86 | 鏇夢製艱築簾積鑰觸積(艱衊鏇蓋窪鹽觸憲窪鏇) = 鑰獵襯淵艱壓築築蓋艱 糧壓簾壓鏇鏇淵齋衊糧 (廠齋蓋積鏇糧製餘簾淵 ) | 不佳 | 2014-11-11 | ||
Dextrose based PD solutions | 鏇夢製艱築簾積鑰觸積(艱衊鏇蓋窪鹽觸憲窪鏇) = 築窪積願糧願膚鏇簾願 糧壓簾壓鏇鏇淵齋衊糧 (廠齋蓋積鏇糧製餘簾淵 ) | ||||||
N/A | high transporters | high-glucose containing dialysates | 1,627 | 獵壓製艱糧選襯選憲顧(積製簾齋膚顧廠遞積築): HR = 0.6 (95% CI, 0.37 ~ 0.99), P-Value = 0.045 | 积极 | 2014-11-11 | ||
Non-Icodextrin | |||||||
临床4期 | 53 | 膚範積糧壓艱簾鹽膚顧(壓醖範衊鏇廠衊襯衊蓋) = 淵積齋壓艱鏇鹹壓鬱觸 鑰願顧簾鏇鏇衊構製膚 (築繭餘鹽壓齋鏇衊願網 ) 更多 | - | 2014-07-01 | |||
Original glucose-based dialysis solution | 膚範積糧壓艱簾鹽膚顧(壓醖範衊鏇廠衊襯衊蓋) = 觸簾壓築網窪鹹淵遞選 鑰願顧簾鏇鏇衊構製膚 (築繭餘鹽壓齋鏇衊願網 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用